Clinical Research

北卡罗来纳大学莱恩伯格综合癌症中心的临床研究计划(CRP)吸引了来自不同癌症相关临床学科的优秀学术人员，以促进临床和实验室相关研究。CRP的开发治疗小组(DTG)是CRP的枢纽，因为RT将临床试验教师与来自主要疾病特定条目的代表聚集在一起，以设计和实施由调查发起的临床试验和相关科学。在过去的6年里，Gl、Gu、血液病、黑色素瘤和胸部恶性肿瘤以及乳腺癌方面的实力得到了特别的增强，这现在是第二个临床研究和翻译计划。CRP还整合了基础科学和人口科学中出现的翻译概念，将它们嵌入到人类研究中。我们以临床试验为导向的国家公认的生物统计学家团队设计和 分析LCCC CRP研究，同时在临床试验方法学方面拥有出色的同行评审资金。 CRP开发和管理研究者发起的、NCI合作小组和制药公司赞助的试验，尽可能整合药理学、分子、遗传学、行为学和流行病学的终点。它的71名成员来自11个部门和学校。我们通过以下方式整合科学 疾病网站，包括外科、放射、内科、儿科和妇科肿瘤学的研究问题，以及方法学和成像问题。我们的项目将为被任命为CTAC指导委员会成员的NCI Wrth Tepper、Goldberg、Socinski和Carey博士提供高级领导。 2009年，该计划的总成本资金为2300万美元，其中包括610万美元的NCI资金。2004-2009年，出版物总数为1,532份；其中21%是方案内出版物，24%是方案间出版物。在过去的六年中，治疗性临床试验从380项增加到848项。CRP的亮点包括乳房和Gl孢子，肝细胞和肾癌的新努力，杰出的 其中包括一项针对多种癌症的基因组芯片能力，一项针对前列腺癌的多中心国防部拨款，一项专注于临床试验方法学的P-01计划，一项国家认可的乳腺癌和老年肿瘤学研究员Hy Muss的招募，以及由新招募人员Howard McLeod领导的个体化治疗研究。CRP作为人类临床试验的渠道和纽带，为UNC LCCC增加了价值 为整个LCCC成员服务的科学研究。

The Clinical Research Program (CRP) at the UNC Lineberger Comprehensive Cancer Center attracts accomplished academic faculty from diverse cancer related clinical disciplines to foster clinical and laboratory linked research. The CRP's Developmental Therapeutics Group (DTG) is CRP's hub, as rt brings together clinical trials faculty with representation from the major disease specific entries to design and implement investigation-initiated clinical trials and correlative science. Over the past 6 years particular strength has been built in Gl, GU, hematologic, melanoma, and thoracic malignancies, as well as Breast Cancer, which is now a second clinical research and translational program. The CRP also integrates translational concepts that emerge from the basic and population sciences, embedding them in human studies research. Our clinical trials oriented group of nationally recognized biostatisticians both design and analyze LCCC CRP studies while having outstanding peer-reviewed funding In clinical trials methodology. The CRP develops and manages investigator initiated, NCI cooperative group, and pharmaceutical company sponsored trials, whenever possible integrating pharmacologic, molecular, genetic, behavioral, and epidemiologic endpoints. Its 71 members come from 11 departments and schools. We integrate science by disease site while including research issues across the spectrum of surgical, radiation, medical, pediatric, and gynecologic oncology, as well as methodology and imaging questions. Our program is providing senior leadership to NCI wrth Drs. Tepper, Goldberg, Socinski and Carey appointed to CTAC steering committees. Program total cost funding in 2009 was $23.0 million, including $6.1 million in NCI funding. In 2004-9, the total number of publications were 1,532; 21% of which were intraprogrammatic and 24% were interprogrammatic. Therapeutic Clinical trials accrual rose from 380 to 848 during the last six years. CRP highlights include Breast and Gl SPOREs, emerging efforts in hepatocellular and renal cancers, outstanding genomic array capabilities in multiple cancers, a multi-center DOD grant in prostate cancer, a P-01 focusing on clinical trials methodology, recruitment of a nationally recognized Breast Cancer and Geriatric Oncology researcher, Hy Muss, and studies in individualized therapy, led by new recruit Howard McLeod. The CRP adds value to the UNC LCCC by acting as the human clinical trials conduit and nexus for clinical and scientific studies that serve the whole LCCC membership.